Q-omics provides the consensus-scored ITGA7 profile across patient tissues and cancer cell-line models. ITGA7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ITGA7 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, ITGA7 protein abundance shows 29,811 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight BLCA, and HNSC as cancer lineages where ITGA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITGA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITGA7 survival associations across molecular data types. ITGA7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITGA7 RNA expression–survival associations across cancer types. High ITGA7 expression shows unfavorable associations in BLCA, UVM, ACC, LGG and COAD, but favorable associations in PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ITGA7 RNA expression.
This table summarizes ITGA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ITGA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITGA7 shows lower tumor expression in BLCA, LUSC, BRCA and UCEC and higher tumor expression in LIHC and KIRC. The BLCA box plot shows higher ITGA7 RNA expression in normal versus tumor tissue (log2 FC = −4.342, t-test p < 0.001).
This table shows molecular features associated with ITGA7 in patient tissues and cancer cell lines. In patient samples, ITGA7 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, ITGA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and OVARY.
